|Study The Effects Of Different Doses Of UK-369,003 In Men With Overactive Bladder|
|A Multi-Center, Randomised, Parallel Group, Double-Blind, Placebo Controlled Estimation Study To Assess The Efficacy And Safety Of Modified Release UK-369,003 In The Treatment Of Men With Storage Lower Urinary Tract Symptoms (LUTS) With And Without Erectile Dysfunction (ED).|
|This is a 12 week study in which different doses of UK-369,003 will be administered to patients with a diagnosis of overactive bladder. Patients will complete a series of questionnaires before treatment, during treatment and after treatment, to assess whether UK-369,003 has improved their symptoms of overactive bladder and erectile function.|
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
|Urinary Bladder, Overactive|
|June 2008 (Final data collection date for primary outcome measure)|
- Male subjects aged 18 years and above
- documented clinical diagnosis of overactive bladder with urinary frequency >= 8 times / 24 hours and number of urgency episodes > 1 episode / 24 hours.
- Neurological diseases known to affect bladder function.
- Urinary tract infection.
|Sexes Eligible for Study:||Male|
|18 Years and older (Adult, Older Adult)|
|Contact information is only displayed when the study is recruiting subjects|
|Australia, Canada, Chile, Colombia, Finland, France, Germany, Greece, Italy, Latvia, Norway, Poland, Slovakia, Spain, Switzerland, United Kingdom|
|Director, Clinical Trial Disclosure Group, Pfizer Inc|
|Study Director:||Pfizer CT.gov Call Center||Pfizer|